News

GlobalData on MSN2mon
Palatin concludes Phase II trial of combination therapy for obesity
a glucagon-like peptide-1 (GLP-1)/gastric inhibitory polypeptide (GIP), to treat obesity. The final output collection and ...
The American Journal of Managed Care5d
Increased Awareness, Novel Interventions Spell New Era for MASLD/MASH: Naim Alkhouri, MD
The future of treating metabolic dysfunction–associated steatohepatitis (MASH) looks brighter than ever, says Naim Alkhouri, MD, as data emerges on newly developed interventions.
Hosted on MSN6mon
Amgen downgraded at Truist on MariTide prospects for obesity
Analyst Robyn Karnauskas wrote that when phase 2 data on MariTide, a GLP-1 receptor and gastric inhibitory polypeptide receptor comes out, it will likely reflect prior data. And given the current ...